Drug Trial News

RSS

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

A phase III clinical trial showed consistent immunogenicity for a freeze-dried formulation of Bavarian Nordic's Modified Vaccinia Ankara.

5 Dec 2022

Trial assesses the impact of two immunomodulators in reducing CV risk among rheumatoid arthritis patients

People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.

5 Dec 2022

New trial to evaluate a potential treatment for irritability in teenagers with autism

A new trial will test whether a medication that targets gut bacteria can also improve irritability in teenagers with autism spectrum disorder.

5 Dec 2022

Trial shows acoziborole drug clears body of African sleeping sickness parasites

Researchers evaluate the efficacy and safety of an oral antimicrobial drug acoziborole in patients with human African trypanosomiasis.

4 Dec 2022

The business of clinical trials is booming. Private equity has taken notice.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.

2 Dec 2022

First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

A Phase 1 clinical trial provides promising results for a broadly neutralizing antibody (bnAb) HIV vaccine, according to a new study.

1 Dec 2022

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity.

1 Dec 2022

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

30 Nov 2022

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases.

30 Nov 2022

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

A drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19, despite this approach being offered to patients, a UK-wide trial, led by Addenbrooke's Hospital and the University of Cambridge has found.

28 Nov 2022

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Patients with high-risk stage III-IV melanoma who received pembrolizumab after their surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon.

23 Nov 2022

Morphine does not reduce worst breathlessness, study finds

Sometimes healthcare professionals treat patients with opioids such as morphine to relieve symptoms, but there has been a lack of evidence as to whether this helps with severe chronic breathlessness.

23 Nov 2022

Hungary sees 116% growth in non-invasive prenatal testing

...

From BGI Genomics 21 Nov 2022

Unique clinical trial in pet dogs could unlock treatment breakthrough for childhood cancers

Telethon Kids Institute is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.

14 Nov 2022

Oral deucravacitinib shows promise in patients with active lupus

Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus.

14 Nov 2022

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab-;a human monoclonal antibody that targets the type I IFN receptor-;in patients with lupus.

14 Nov 2022

Duke scientists join team involved in the first use of fetal therapy for Pompe disease

Experts at Duke Health were among a multi-national team involved in treating a fetus for infantile-onset Pompe disease using an enzyme replacement therapy - a first in the world.

9 Nov 2022

Previous
1
...
26
27
28
29
30
31
32
...
1143
Next

Drug Trial News

T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

Trial assesses the impact of two immunomodulators in reducing CV risk among rheumatoid arthritis patients

New trial to evaluate a potential treatment for irritability in teenagers with autism

Trial shows acoziborole drug clears body of African sleeping sickness parasites

The business of clinical trials is booming. Private equity has taken notice.

First-in-humans test provides promising results for a broadly neutralizing antibody HIV vaccine

Phase 2 clinical trial of DS-1211 begins for individuals with Pseudoxanthoma Elasticum

Phase 2/3 clinical trial shows that Clover’s vaccine candidate reduces household transmission of SARS-CoV-2

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

Oral anticoagulant does not help patients recovering from moderate and severe COVID-19

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Morphine does not reduce worst breathlessness, study finds

Hungary sees 116% growth in non-invasive prenatal testing

Unique clinical trial in pet dogs could unlock treatment breakthrough for childhood cancers

Oral deucravacitinib shows promise in patients with active lupus

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Duke scientists join team involved in the first use of fetal therapy for Pompe disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News